tradingkey.logo

Integra Lifesciences Holdings Corp

IART
View Detailed Chart

15.380USD

+0.580+3.92%
Close 09/18, 16:00ETQuotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM

Integra Lifesciences Holdings Corp

15.380

+0.580+3.92%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.92%

5 Days

-0.06%

1 Month

+8.39%

6 Months

-33.48%

Year to Date

-32.19%

1 Year

-10.37%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
89 / 207
Overall Ranking
237 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 12 analysts
Hold
Current Rating
16.429
Target Price
+10.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 6.94M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is -2.26, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 89.38M shares, decreasing 17.32% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 7.50M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Ticker SymbolIART
CompanyIntegra Lifesciences Holdings Corp
CEOMs. Mojdeh Poul
Websitehttps://www.integralife.com/
KeyAI